Naltrexone and Buprenorphine Market By Product Type (Naltrexone, Buprenorphine); By Route of Administration (Oral Including Transmucosal, Transdermal/Implants, Injectables); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Naltrexone and Buprenorphine Market - Global Market Report Description, 2026–2032  – (Updated On: 31-Aug-2026)

What Is the Current Naltrexone and Buprenorphine Market Size and How Is the Therapeutic Landscape Evolving?

The Global Naltrexone and Buprenorphine Market was valued at USD 3.85 billion in 2025 and is projected to reach USD 6.35 billion by 2032, expanding at a CAGR of 7.4% during 2026–2032, according to Strategic Market Research.

 

Naltrexone and buprenorphine are established prescription medicines used across overlapping but clinically distinct care pathways. Buprenorphine is used primarily for opioid use disorder (OUD) and, in selected transdermal and buccal formulations, for severe persistent pain requiring continuous opioid treatment. Naltrexone is used for alcohol use disorder (AUD) and to prevent relapse to opioid dependence after detoxification. These uses create a market spanning addiction medicine, office-based care, specialty treatment programs, pharmacies and selected pain-management settings.

 

Buprenorphine partially activates the mu-opioid receptor, helping suppress withdrawal and craving while producing less maximal receptor activation than a full opioid agonist. Naltrexone blocks opioid receptors and should not routinely be initiated while physiological opioid dependence persists because it can precipitate severe withdrawal. FDA-approved U.S. products include transmucosal buprenorphine and buprenorphine-naloxone medicines, monthly Sublocade, weekly or monthly Brixadi, monthly Vivitrol, and pain products such as Butrans and Belbuca. FDA labeling changes in 2025 allowed Sublocade initiation after a single transmucosal buprenorphine dose and clarified individualized maintenance dosing for transmucosal products, reducing practical friction in some treatment pathways.

 

The treatment pool remains materially larger than current medication use. SAMHSA estimated that 4.0 million people aged 12 or older in the United States had past-year OUD in 2025, but only 15.7% received medication for OUD. The same survey estimated 25.7 million people with past-year AUD, while only 2.6% received an approved medication for AUD. The commercial opportunity therefore depends less on identifying a new disease population and more on treatment initiation, persistence, pharmacy completion, dosing convenience and integration into routine care.

 

Executive Market Snapshot: Segment Leaders, Growth Rates and Regional Positioning

By Product Type

• Naltrexone accounted for 30.0% of the market in 2025, representing USD 1.155 billion, and is projected to expand at a CAGR of 5.4%; its dual role in AUD and post-detoxification OUD treatment supports use, while initiation requirements and approaching injectable-generic competition moderate value growth.

• Buprenorphine held 70.0% of the market in 2025 at USD 2.695 billion and is projected to expand at a CAGR of 8.2%; scale comes from OUD maintenance, generic transmucosal products, long-acting injections and selected chronic-pain formulations.

 

By Route of Administration

• Oral, including transmucosal products under the SMR taxonomy, represented 55.0% of the market in 2025 at USD 2.118 billion and is projected to grow at a CAGR of 6.0%, reflecting broad generic availability and dosing flexibility.

• Transdermal/Implants accounted for 8.0% of the market in 2025 at USD 0.308 billion and a CAGR of 6.5%; current value is weighted toward buprenorphine pain patches, while the commercial contribution from OUD implants is limited.

• Injectables held 37.0% of the market in 2025 at USD 1.425 billion and are projected to record the fastest CAGR of 9.5%, supported by longer dosing intervals and provider-administered treatment models.

 

By Distribution Channel

• Hospital Pharmacies accounted for 35.0% of the market in 2025 at USD 1.348 billion and a CAGR of 8.0%; the model includes hospital-owned outpatient and clinical-site acquisition for provider-administered products where applicable.

• Retail Pharmacies & Drug Stores led with 55.0% of the market in 2025 at USD 2.118 billion and a CAGR of 6.6%, reflecting the large base of oral, sublingual, buccal and transdermal prescriptions.

• Online Pharmacies represented 10.0% of the market in 2025 at USD 0.385 billion and are projected to expand at a CAGR of 9.6%; the category refers to licensed digital and mail-order fulfillment for eligible self-administered products, not direct-to-patient supply of depot injections.

 

By Geography

• North America held 52.0% of the market in 2025 at USD 2.002 billion and a CAGR of 7.2%, combining high medication utilization, public-payer coverage and the strongest concentration of branded long-acting products.

• Europe accounted for 23.0% of the market in 2025 at USD 0.886 billion and a CAGR of 6.3%, supported by established opioid agonist treatment systems and country-level use of buprenorphine-based medicines.

• Asia-Pacific represented 15.0% of the market in 2025 at USD 0.578 billion and is projected to grow at a CAGR of 9.5%, with Australia providing a leading example of community pharmacy access and long-acting buprenorphine use.

• Latin America held 6.0% of the market in 2025 at USD 0.231 billion and a CAGR of 7.8%; growth is expected to remain concentrated in countries and urban systems with stronger specialist access, product registration and reimbursement.

• Middle East & Africa accounted for 4.0% of the market in 2025 at USD 0.154 billion and a CAGR of 7.4%, with market formation shaped by uneven addiction-treatment infrastructure, pain-product access and public procurement capacity.

 

The Treatment-Pathway Divide: Buprenorphine Initiation, Naltrexone Induction and Commercial Conversion

Buprenorphine participates earlier and more continuously in the OUD pathway. Transmucosal products can be initiated in office-based or specialty settings and titrated to control withdrawal and craving, while Sublocade and Brixadi extend exposure over weekly or monthly intervals. The May 2025 FDA labeling update for transmucosal buprenorphine clarified that maintenance dosing should be individualized and that doses above 24 mg per day may be appropriate for some patients, helping prescribers manage patients whose exposure to potent illicit opioids makes stabilization more difficult.

Naltrexone occupies a different position. Oral naltrexone and monthly Vivitrol do not maintain opioid dependence; they block opioid effects and are used after detoxification. Current Vivitrol labeling recommends an opioid-free interval of at least 7 to 10 days before initiation, and patients transitioning from methadone or buprenorphine may remain vulnerable to precipitated withdrawal for up to two weeks. Naltrexone also participates in AUD treatment, giving the molecule an indication base beyond OUD and making alcohol-treatment penetration commercially relevant to its long-term value.

The induction gap is well documented. In the randomized X:BOT trial, 94% of participants assigned to buprenorphine-naloxone successfully initiated treatment compared with 72% assigned to extended-release naltrexone. Once patients were successfully inducted, relapse outcomes were broadly similar, indicating that much of the practical difference arose before the first sustained treatment period rather than after stable therapy had begun.

A comparative-effectiveness study published in 2026 used Massachusetts administrative data covering 36,752 individuals and 106,052 medically managed opioid-withdrawal discharge episodes from 2014 to 2018. Buprenorphine-naloxone was initiated after 13.4% of episodes compared with 4.5% for extended-release naltrexone. Adjusted 24-week nonfatal overdose incidence was 11.6% and 13.9%, respectively, while all-cause mortality was 1.4% in both groups. Because the analysis was observational and a sensitivity analysis limited to the first discharge per person did not retain a statistically significant overdose difference, the result is best interpreted as evidence about real-world initiation and continuity rather than definitive clinical superiority.

Naltrexone should not be described as a routine concurrent treatment for an opioid-dependent patient receiving buprenorphine. Small historical studies examined carefully controlled combination or transition protocols, including very-low-dose naltrexone during buprenorphine tapering, but these protocols are not equivalent to ordinary co-prescribing and do not remove the opioid-free requirement in current Vivitrol labeling.

The broad molecule market also includes a separate pain pathway. Butrans is indicated for severe pain requiring continuous long-term opioid treatment and is not approved for the management of addictive disorders; Belbuca is a buccal buprenorphine film used for severe persistent pain. These products support the transdermal and buccal portions of the market but should not be used as evidence of OUD-treatment expansion.

 

Product Value Pools: Buprenorphine Leadership and Naltrexone’s Dual-Indication Position

Naltrexone accounted for 30.0% of the market, representing USD 1.155 billion in 2025, and is projected to expand at a CAGR of 5.4% during 2026–2032. Its position reflects two commercially distinct uses: lower-cost oral therapy across AUD and selected abstinence-oriented OUD care, and the higher-value monthly Vivitrol franchise. The need for detoxification before OUD initiation limits conversion relative to buprenorphine, while the FDA-approved first generic extended-release naltrexone introduces a future pathway for broader payer access and branded price pressure. Alkermes and Teva therefore influence the segment through different levers: branded dual-indication positioning versus complex-injectable generic competition.

Buprenorphine held 70.0% of the market, equivalent to USD 2.695 billion in 2025, and is projected to expand at a CAGR of 8.2%. The segment combines large-volume generic transmucosal treatment with premium long-acting injections and selected pain products. Indivior and Braeburn compete in OUD through Sublocade and Brixadi, while Dexcel Pharma USA owns the U.S. rights to Zubsolv and Collegium participates through Belbuca in chronic pain. This breadth gives buprenorphine more routes to value creation than a single-indication molecule, but it also requires the market model to distinguish addiction-treatment volume from pain-product revenue.

The most important commercial split is not simply naltrexone versus buprenorphine; it is commoditized daily therapy versus differentiated long-acting treatment. Generic tablets and films support patient volume and broad coverage, while depot injections can increase revenue per treated patient and shift product acquisition toward provider and specialty channels. That value migration explains why buprenorphine can expand faster than the overall market even when the underlying number of patients grows more slowly.

 

From Daily Dosing to Depot Therapy: Route-of-Administration Value Migration

Oral products, including transmucosal formulations under the supplied SMR route taxonomy, represented 55.0% of the market, equivalent to USD 2.118 billion in 2025, and are projected to expand at a CAGR of 6.0%. The category combines swallowed oral naltrexone with sublingual and buccal buprenorphine products. It remains the largest route because generic availability, dose adjustment and conventional pharmacy dispensing support scale. FDA-approved examples include Suboxone, Zubsolv and generic buprenorphine or buprenorphine-naloxone products, while the 2025 labeling update supports more individualized maintenance dosing in OUD.

Transdermal/Implants accounted for 8.0% of the market, representing USD 0.308 billion in 2025, and are projected to grow at a CAGR of 6.5%. This route is primarily a chronic-pain segment rather than an OUD growth engine in the current U.S. market. Butrans and generic transdermal systems provide multi-day analgesic delivery, while the commercial contribution from buprenorphine implants is limited relative to patches and depot injections. The segment benefits from sustained delivery but remains narrower because patient selection, opioid-safety requirements and competition from non-opioid or alternative analgesic strategies constrain broad use.

Injectables accounted for 37.0% of the market, representing USD 1.425 billion in 2025, and are projected to record the fastest CAGR of 9.5%. Sublocade provides monthly subcutaneous buprenorphine, Brixadi offers weekly and monthly subcutaneous dosing, and Vivitrol supplies monthly intramuscular naltrexone. Longer intervals reduce reliance on daily self-administration and are particularly relevant where treatment continuity, diversion control, medication custody or follow-up are operational concerns. WHO’s April 2026 rapid communication also introduced a conditional recommendation for long-acting injectable buprenorphine while noting that the complete updated guideline remained forthcoming.

Australia demonstrates how care setting can influence formulation mix. On a June 2025 snapshot day, 60% of opioid pharmacotherapy clients received a buprenorphine formulation, and the national network included 3,241 dosing sites, of which 77% were pharmacies. The system shows that long-acting and community-dispensed treatment can coexist rather than requiring a single centralized model.

 

From Prescription to Product Access: Pharmacy Channels and Fulfilment Economics

Hospital Pharmacies accounted for 35.0% of the market, representing USD 1.348 billion in 2025, and are projected to expand at a CAGR of 8.0%. Within the SMR model, this category includes hospital-owned outpatient pharmacies and clinical-site product acquisition associated with provider-administered treatment where applicable; it should not be interpreted as meaning that all depot products flow through inpatient pharmacies. The channel is commercially important when withdrawal management, comorbidities, specialty care or injectable administration require closer clinical coordination.

Retail Pharmacies & Drug Stores held 55.0% of the market, representing USD 2.118 billion in 2025, and are projected to expand at a CAGR of 6.6%. Retail dispensing remains central to oral naltrexone, transmucosal buprenorphine and transdermal pain formulations. The channel’s market position depends on stocking, payer adjudication, controlled-substance workflows and the patient’s ability to complete the first fill. It therefore remains a major conversion point between a prescription being written and medication actually being started.

Online Pharmacies represented 10.0% of the market, equivalent to USD 0.385 billion in 2025, and are projected to record a CAGR of 9.6%. The category refers to licensed digital-pharmacy and mail-order fulfillment for eligible self-administered products, supported by electronic prescribing and remote care coordination. It has limited direct relevance to Sublocade, Brixadi and Vivitrol because those products are administered by healthcare professionals. The commercial advantage is convenience for established oral or transmucosal therapy; the constraint is that digital prescribing does not by itself solve payer rejection, local stocking or first-fill abandonment.

 

Global Market Footprint: Regional Treatment Infrastructure and Commercial Expansion

North America accounted for 52.0% of the market, representing USD 2.002 billion in 2025, and is projected to expand at a CAGR of 7.2%. The region combines a large OUD and AUD treatment pool, broad pharmacy dispensing, Medicaid and Medicare coverage, and the strongest competition among long-acting branded products. Commercial activity from Indivior, Braeburn and Alkermes supports premium injectable value, while extensive generic transmucosal use maintains volume. The proposed Indivior-Supernus combination, announced in August 2026 but not yet completed, could also change commercial reach and capital allocation around Sublocade.

Europe held 23.0% of the market, equivalent to USD 0.886 billion in 2025, and is projected to grow at a CAGR of 6.3%. EUDA reported that 36% of opioid agonist treatment clients across reporting European countries received buprenorphine-based medicines in 2024, compared with 61% receiving methadone. England recorded 138,255 adults in treatment for opiate problems during 2024–25. NICE continues to position oral buprenorphine as an opioid-dependence maintenance option and naltrexone for detoxified, formerly opioid-dependent people motivated to remain in an abstinence program, illustrating the different treatment roles within established national systems.

Asia-Pacific represented 15.0% of the market, equivalent to USD 0.578 billion in 2025, and is projected to record the fastest regional CAGR of 9.5%. Australia provides the strongest current utilization evidence: 34,665 clients, or 60% of opioid pharmacotherapy clients, received a buprenorphine formulation on the June 2025 snapshot day, and pharmacies represented 77% of dosing sites. The broader regional forecast also reflects improving pharmaceutical access and pain-treatment use, although regulatory pathways and public funding differ substantially across Japan, China, India, South Korea, Australia and Southeast Asia.

Latin America accounted for 6.0% of the market, representing USD 0.231 billion in 2025, and is projected to expand at a CAGR of 7.8%. SMR’s estimate reflects a market in which lower-cost oral products and selected pain formulations are more accessible than premium long-acting OUD products in many settings. Expansion is expected to remain concentrated in larger urban health systems and countries where addiction medicine, private coverage, product registration and specialty distribution are more developed; the region should not be treated as a uniform access environment.

Middle East & Africa held 4.0% of the market, equivalent to USD 0.154 billion in 2025, and are projected to expand at a CAGR of 7.4%. Commercial penetration varies sharply between higher-income Gulf markets, countries with established opioid-substitution programs and lower-resource systems with limited specialty access. WHO estimated in April 2026 that 64 million people worldwide were living with drug-use disorders and fewer than 10% received treatment, but this global treatment gap should be used as context rather than as direct proof of the region’s share. The regional opportunity is therefore linked to treatment-system formation, public procurement and reliable medicine supply rather than immediate conversion to premium formulations.

 

Competitive Landscape: Long-Acting Innovation, Generic Pressure and Portfolio Strategy

Competition is divided between high-volume generic oral or transmucosal products and differentiated long-acting formulations. Companies compete through dosing interval, initiation pathway, provider workflow, indication breadth, payer access, patient persistence and geographic commercialization. The buprenorphine market is shifting toward depot formulations, while the naltrexone market faces a potential change in branded economics as complex-injectable generic competition approaches.

 

Company	Relevant portfolio	Current strategic issue
Indivior	Sublocade; Suboxone-related buprenorphine franchise	Scaling monthly LAI treatment; proposed Supernus merger
Alkermes	Vivitrol extended-release naltrexone	Dual AUD/OUD position; expected generic inflection
Braeburn / Camurus	Brixadi in the U.S.; Buvidal internationally	Weekly/monthly flexibility and share gains in LAI buprenorphine
Dexcel Pharma USA	Zubsolv buprenorphine-naloxone	New U.S. franchise ownership after 2025 acquisition
Teva	FDA-approved generic extended-release naltrexone	Approval secured; settlement-linked commercial timing
Collegium	Belbuca buprenorphine buccal film	Pain-market exposure within the broader molecule scope

Indivior
Indivior’s central asset is Sublocade, an FDA-approved monthly extended-release buprenorphine injection for moderate-to-severe OUD. Its differentiation lies in rapid transition from transmucosal initiation, monthly administration and a large established U.S. treatment base. Indivior reported total Sublocade net revenue of USD 253 million in Q2 2026, up 21% year over year, and stated that more than 545,000 U.S. patients had been prescribed the product since launch as of June 30, 2026. On August 3, 2026, Indivior and Supernus announced a proposed all-stock merger of equals expected to close in the fourth quarter, subject to approvals and closing conditions; the transaction must not be described as completed.

 

Alkermes
Alkermes competes through Vivitrol, the once-monthly extended-release injectable naltrexone used for alcohol dependence and prevention of relapse to opioid dependence following detoxification. The company reported Q2 2026 Vivitrol revenue of USD 124.5 million. Its near-term strategic issue is generic entry: Alkermes’ 2025 Form 10-K states that Teva may market a generic beginning January 15, 2027, or earlier under specified circumstances. Alkermes and Amneal terminated their separate authorized-generic supply agreement on July 6, 2026, so that arrangement should not be presented as an active defensive strategy.

 

Braeburn and Camurus
Braeburn markets Brixadi in the United States, while Camurus commercializes the underlying long-acting buprenorphine platform as Buvidal in international markets. Brixadi is FDA approved in weekly and monthly formulations, giving clinicians more dosing-frequency flexibility than a monthly-only model. Camurus reported that Brixadi royalty revenue increased 42% year over year to SEK 127 million in Q2 2026. The commercial relevance is not the royalty figure alone; it is evidence that a second long-acting buprenorphine franchise is gaining scale in a category previously led by Sublocade.

 

Dexcel Pharma USA
Dexcel Pharma USA owns the U.S. rights to Zubsolv, a buprenorphine-naloxone sublingual tablet for OUD. Orexo completed the transfer on December 31, 2025, for USD 91 million plus inventory consideration, with additional contingent consideration linked to future sales. Zubsolv gives Dexcel an established branded position within the large transmucosal segment, where differentiation depends on prescriber familiarity, formulary placement, patient preference and execution against extensive generic competition.

 

Teva Pharmaceutical Industries
Teva holds FDA approval for the first generic naltrexone extended-release injectable suspension, 380 mg per vial. FDA approval in July 2023 established regulatory equivalence for a technically complex monthly microsphere product used in alcohol dependence and prevention of relapse to opioid dependence. Approval should not be equated with unrestricted commercial launch; disclosed settlement terms permit U.S. marketing from January 15, 2027, or earlier under specified circumstances. Teva’s eventual entry could improve payer leverage and access while reducing branded revenue per treated patient.

 

Collegium Pharmaceutical
Collegium participates in the broader molecule market through Belbuca, an FDA-approved buprenorphine buccal film for severe persistent pain requiring an opioid when alternative treatments are inadequate. The product is outside the OUD pathway but is relevant to the supplied oral/transmucosal market value. Collegium reported Belbuca net revenue of USD 57.7 million in Q2 2026, up 10% year over year, demonstrating that pain formulations remain a meaningful commercial component when the market is defined by molecule rather than addiction indication alone.

 

The 2032 Inflection Map: Long-Acting Conversion, Generic Entry and Corporate Reshaping

The principal value driver is conversion from daily therapy to long-acting buprenorphine. This does not require patient numbers to grow at the same rate as revenue because monthly or weekly provider-administered products carry different acquisition, reimbursement and service economics from generic tablets and films. The main execution risks are payer authorization, product availability, clinical-site capacity and whether patients remain connected to care long enough to receive repeat doses.

Naltrexone presents the opposite value tension. AUD and post-detoxification OUD provide a broad clinical base, but the molecule’s OUD conversion remains limited by the opioid-free initiation period. At the same time, expected generic extended-release injectable entry from 2027 can expand payer choice while compressing the branded value of Vivitrol. Patient growth and market-value growth may therefore move in different directions within the naltrexone segment.

Corporate ownership is another near-term variable. The proposed Indivior-Supernus combination could expand commercialization capabilities around Sublocade if completed, while Dexcel’s acquisition of Zubsolv changes ownership within the transmucosal franchise. These developments should be monitored alongside Brixadi share gains and Vivitrol generic timing because they affect field reach, contracting, capital allocation and portfolio priorities rather than clinical efficacy alone.

 

Selected Market Events and Forward Watchpoints

Date	Event	Commercial relevance
May 2023	FDA approves weekly and monthly Brixadi	Introduces a second differentiated long-acting buprenorphine franchise in the U.S.
Jul 2023	FDA approves Teva’s generic XR naltrexone	Establishes a future complex-generic alternative to Vivitrol.
Feb-May 2025	Sublocade and transmucosal buprenorphine labeling updates	Reduces initiation friction and clarifies individualized dosing.
Dec 2025	Dexcel acquires U.S. Zubsolv rights	Transfers a mature transmucosal franchise to a new commercial owner.
Apr 2026	WHO issues rapid communication on updated opioid-dependence recommendations	Supports international relevance of long-acting injectable buprenorphine; full guideline remains forthcoming.
Jul 2026	Alkermes and Amneal terminate authorized-generic agreement	Removes an anticipated authorized-generic pathway from the disclosed strategy.
Aug 2026	Indivior and Supernus announce proposed merger	Could alter Sublocade commercialization and CNS portfolio scale if completed.
Jan 2027	Earliest disclosed Teva license date under settlement	Potential inflection for Vivitrol pricing, payer leverage and branded share.

The forecast has four material sensitivities. Upside would come from faster medication-treatment penetration, wider conversion to long-acting buprenorphine, improved first-fill completion and broader regional reimbursement. Downside would come from slower clinical-site adoption, persistent pharmacy abandonment, deeper generic price erosion, higher rebates or a market mix that shifts toward lower-priced oral products. The 7.4% CAGR therefore reflects a combination of treated-patient expansion and product-mix change rather than a single epidemiological trend.

 

SMR Market Model: Scope, Revenue Basis and Forecast Reconciliation

Strategic Market Research treated the 2025 global value, 2032 forecast, segment shares and segment CAGRs as the approved quantitative baseline. The forecast was reconciled across product type, route of administration, distribution channel and geography. Product-type shares total 100.0%; route shares total 100.0%; distribution shares total 100.0%; and regional shares total 100.0%. Implied 2032 segment totals reconcile with the global forecast after normal rounding differences.

The market is measured at the manufacturer sales level for branded and generic prescription products within the stated scope. Combination products containing buprenorphine and naloxone are assigned to the buprenorphine category because buprenorphine is the principal treatment component. The supplied Oral category includes swallowed oral and transmucosal formulations. Hospital Pharmacies aggregate hospital-owned outpatient and eligible clinical-site acquisition, while Online Pharmacies refer to licensed digital or mail-order dispensing of eligible self-administered products.

Clinical, epidemiological, reimbursement and company evidence was drawn from FDA, SAMHSA, CMS, Medicaid, WHO, EUDA, AIHW, UK public-health sources, peer-reviewed journals, SEC filings and official company announcements. External syndicated market-research estimates were not used. Regulatory approval, commercial launch, proposed transactions and company-reported financial results are identified separately to avoid treating them as interchangeable evidence types.

 

Naltrexone and Buprenorphine Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.85 Billion
Revenue Forecast in 2032	USD 6.35 Billion
Overall Growth Rate	CAGR of 7.4% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product Type, By Route of Administration, By Distribution Channel, By Geography
By Product Type	Naltrexone, Buprenorphine
By Route of Administration	Oral, Transdermal/Implants, Injectables
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Australia, Japan, China, India, South Korea, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Large untreated OUD and AUD populations, expanded buprenorphine prescribing access, conversion toward long-acting injectable formulations, public-payer coverage, community-pharmacy participation, individualized dosing, and wider integration of medication treatment into routine care
Customization Option	Available upon request